digital currency counter, Top

Stellantis: After rejoining ACEA, it will be consistent with its proposal. Jean-Philippe Imparato, head of Europe for Stellantis, said on Thursday that Stellantis decided to rejoin the European automobile lobby group ACEA, which means that the automobile manufacturer will immediately be consistent with the group's proposal. Stellantis said last week that he would rejoin ACEA, and the group withdrew in early 2023. Under the leadership of Carlos Tavares, CEO who resigned earlier this month, the group had previously opposed ACEA's call for reducing the EU's intermediate carbon emission reduction target in 2025, saying that it might bring billions of dollars in losses to the automobile industry.The dollar index DXY fell 10 points in the short term and is now reported at 106.72.European Central Bank President Lagarde: Labor cost growth will slow down.

Trump: For me, the stock market is everything and very important.The yield of German 2-year government bonds fell by 3 basis points to 1.92%, the lowest since December 3.European Central Bank President Lagarde: Reiterating the European Central Bank policy statement.

European Central Bank President Lagarde: Reiterating the European Central Bank policy statement.Wal-Mart Nuclear Materials: 224G high-speed communication line products have been delivered stably in batches, and Wal-Mart Nuclear Materials has released a record of investor relations activities. The company's demand for high-speed communication line orders continues to grow, and the machines are running at full capacity. It is expected that a number of key equipment will arrive in 2025. The 224G high-speed communication line products of Le Ting Zhilian, a subsidiary, have been delivered to direct customers in batches. In addition, the company's subsidiary has established a long-term and stable supply cooperation relationship with Huawei and signed a confidentiality agreement with it.Baiyang Pharmaceutical Group signed an agreement with Peking University Hospital. On December 12, Baiyang Pharmaceutical Group signed a cooperation agreement with Peking University No.1 Hospital, and obtained the exclusive right to patent, clinical development and registration, production and marketing of "targeted integrin small molecule inhibitor" in Peking University Hospital.